pharmatex 18,9 mg pesāriji
laboratoire innotech international sas, france - benzalkonija hlorīds - pesārijs - 18,9 mg
pharmatex 20 mg vaginālās tabletes
laboratoire innotech international sas, france - myristalkonii chloridum - vaginālā tablete - 20 mg
pharmatex 12 mg/g vaginālais krēms
laboratoire innotech international sas, france - benzalkonija hlorīds - vaginālais krēms - 12 mg/g
pharmatex 18,9 mg mīkstās vaginālās kapsulas
laboratoire innotech international sas, france - benzalkonija hlorīds - vaginālā kapsula, mīkstā - 18,9 mg
furadonīns 100 mg tabletes
olainfarm, as, latvia - nitrofurantoīns - tablete - 100 mg
bleomycin medac 15000 sv pulveris injekciju šķīduma pagatavošanai
medac gesellschaft für klinische spezialpräparate mbh, germany - bleomicīna sulfāts - pulveris injekciju šķīduma pagatavošanai - 15000 sv
methotrexate orion 2,5 mg tabletes
orion corporation, finland - metotreksāts - tabletes - 2,5 mg
methotrexate orion 10 mg tabletes
orion corporation, finland - metotreksāts - tabletes - 10 mg
bleomycin medac 30000 sv pulveris injekciju šķīduma pagatavošanai
medac gesellschaft für klinische spezialpräparate mbh, germany - bleomicīna sulfāts - pulveris injekciju šķīduma pagatavošanai - 30000 sv
volibris
glaxosmithkline (ireland) limited - ambrisentan - hipertensija, plaušu slimība - antihipertensīvie līdzekļi, - volibris is indicated for treatment of pulmonary arterial hypertension (pah) in adult patients of who functional class (fc) ii to iii, including use in combination treatment (see section 5. efficacy has been shown in idiopathic pah (ipah) and in pah associated with connective tissue disease. volibris is indicated for treatment of pah in adolescents and children (aged 8 to less than 18 years) of who functional class (fc) ii to iii including use in combination treatment. efficacy has been shown in ipah, familial, corrected congenital and in pah associated with connective tissue disease (see section 5.